Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Influenza virus vaccine 2009-2010 formulation · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 | EXPERIMENTAL | Participants aged 18 to 59 years at enrollment. |
| Group 2 | EXPERIMENTAL | Participants aged 60 years or older at enrollment. |
| Name | Type | Description |
|---|---|---|
| Influenza virus vaccine 2009-2010 formulation | BIOLOGICAL | 0.1 mL, Intradermal |
Inclusion Criteria: * Aged 18 to 59 years (i.e., to the day before the 60th birthday) or 60 years or older (from the day of the 60th birthday) on the day of inclusion * Provision of a signed informed consent * Able to attend all scheduled visits and comply with all trial procedures * For a woman of...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
It is an inactivated, split virion influenza vaccine developed by Sanofi for the Northern Hemisphere 2009-2010 season. It is designed to protect against seasonal influenza and was studied for administration by the intradermal route. The vaccine is an infectious disease product in Sanofi's influenza vaccine portfolio.
It is used for the prevention of influenza, specifically the seasonal influenza strains circulating in the Northern Hemisphere during the 2009-2010 season. The clinical study enrolled healthy adult volunteers aged 18 years and older. It is given to reduce illness caused by influenza virus infection.
Sanofi develops the influenza virus vaccine 2009-2010 formulation. Sanofi trades on the New York Stock Exchange under the ticker SNY. The company is a major manufacturer of seasonal and pandemic influenza vaccines.
The influenza virus vaccine 2009-2010 formulation is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. It is an investigational vaccine and is not described as approved.
The influenza virus vaccine 2009-2010 formulation was studied in one completed Phase 2 trial, NCT00945438, titled Study of the Influenza Vaccine (Split Virion, Inactivated) Northern Hemisphere 2009-2010 Formulation (Intradermal Route). The trial enrolled 131 participants in France, used a controlled design, and included healthy volunteers aged 18 years and older.